|
|
|
| Curative effect of docetaxel injection combined with nedaplatin for treating advanced ovarian cancer and its influence on the serum carbohydrate antigen 125 and human epididymis protein 4 levels and immune function of the patients |
| Guang'an People's Hospital, Guang'an, Sichuan Province, 638000 |
|
|
|
|
Abstract To explore the curative effect of docetaxel (DOC) injection combined with nedaplatin (NDP) for treating advanced ovarian cancer (OC )of the patients, and to study the influence on the serum carbohydrate antigen 125 (CA125), human epididymis protein 4 (HE4) levels and immune function of the patients. Methods: The clinical data of 80 patients with advanced OC from March 2016 to June 2018 were collected retrospectively. These patients were divided into group A (42 patients with DOC injection combined with NDP for chemotherapy) and group B (38 patients with paclitaxel combined with cisplatin for chemotherapy). The serum CA125 and HE4 levels, immune function, curative effect, and the incidence of adverse reactions of the patients before and after chemotherapy were compared between the two groups. The 1-year and 2-year survival rates of the patients in the two groups were followed up and counted. Results: After treatment, there were no significant differences in disease control rate and therapyeffective rate of the patients between two groups (P＞0.05). The serum levels of CA125 (28.32±9.74 U/ml) and HE4 (58.49±13.25 pmol/L) of the patients in group A were significant lower than those (33.54±10.46 U/ml and 66.26±16.46 pmol/L) of the patients in group B. The levels of CD3+, CD4+, CD8+ and natural killing (NK) of the patients in group A were significant higher than those of the patients in group B (all P＜0.05). There was no significant difference in the survival rate within 1-year (83.3% vs. 65.8%) of the patients between the two groups (P＞0.05), and the survival rate within 2-year of the patients in group A (66.7%) was significant higher than that (44.7%) of the patients in group B (P＜0.05). There was no significant difference in the incidence of abnormal liver and kidney function of the patients between the two groups (P＞0.05), but the incidences of leucopenia and gastrointestinal reaction of the patients in group A were significant lower than those of the patients in group B (P＜0.05). Conclusion: DOC combined with NDP for treating the patients with advanced OC can effectively reduce their serum CA125 and HE4 levels, decrease their immune function damage, alleviate their adverse reactions due to chemotherapy, and improve their survival time.
|
|
|
|
|
|
|
|
|
